AlphaYou
Overview
Smart money at a glance
Filings to Oct 1, 2026No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- $0No open-market trades
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 1 added, 0 cutMore adding
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Key stats
Fundamentals Sep 30- Open
- $18.68
- 52-wk high
- $25.32
- High
- $18.74
- 52-wk low
- $14.68
- Low
- $18.38
- Prev close
- $18.80
- Mkt cap
- $1.97B
- Volume
- 1.37M
- Fwd P/E
- 19.2x
- Beta
- 0.26
- P/S
- 1.0x
- P/B
- 1.3x
- Profit margin
- -6.9%
- Op margin
- +13.0%
- ROE
- -9.5%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about SRPT filings
Are insiders buying or selling Sarepta Therapeutics Inc (SRPT) stock?
Neither. Sarepta Therapeutics Inc (SRPT) insiders filed no open-market purchases or sales in the 90 days to Oct 1, 2026, according to SEC Form 4 filings.
Which members of Congress have traded SRPT recently?
None. No member of Congress disclosed a SRPT trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this SRPT smart-money data?
This summary uses filings available on Oct 1, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position.
What funds are doing
Buys/Adds (2)
- MW
Marshall Wace
$23.9M
added
- TS
Two Sigma
$47.4M
added
Sells/Trims (1)
- DS
D.E. Shaw
$22.8M
trimmed
How top traders are positioned
No tracked top-trader positions in SRPT right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in 23.5% above what analysts expected.
Earnings per share
$0.34 expected
Reports Nov 2, 2026, in 32 days
Financials
Is the business strong?
This company is not yet profitable.
- Net margin
- -6.9%
- Forward P/E
- 19.16
- Market cap
- $2.0B
Valuation
- P/S1.00
- P/B1.31
Quality
- Operating margin13.0%
- ROE-9.5%
- ROA-1.1%
Growth
- Beta0.26
Technicals
Price structure
This stock is under pressure, and looks oversold after a sharp drop.
Trend
Under pressure
0 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace